Anika Therapeutics (ANIK) Total Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has reported Total Current Liabilities for 17 consecutive years, with $22.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 37.72% year-over-year to $22.1 million in Q2 2026; TTM through Jun 2026 was $22.1 million, a 37.72% increase from a year earlier, with the FY2025 full-year figure at $21.9 million, down 6.0% from the prior year.
• Total Current Liabilities was $22.1 million for Q2 2026 at Anika Therapeutics, up from $21.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $31.1 million in Q4 2023 and troughed at $16.1 million in Q2 2025.
• A 5-year average of $24.6 million and a median of $25.8 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities plunged 42.54% in 2022 and jumped 37.72% in 2026, its largest moves.
• Over 5 years, Total Current Liabilities stood at $27.9 million in 2022, then grew by 11.27% to $31.1 million in 2023, then decreased by 24.96% to $23.3 million in 2024, then dropped by 6.0% to $21.9 million in 2025, then gained by 1.09% to $22.1 million in 2026.
• The last three Total Current Liabilities figures came in at $22.1 million (Q2 2026), $21.0 million (Q1 2026), and $21.9 million (Q4 2025), per Business Quant data.